₹15.77
▲ +0.03 +0.19%
17 Jul 2026
NSE Listed
GSM 0Ortin Global Ltd (ORTINGLOBE)
20-day avg volume: 25K shares
| Metric | Jun 2011 | Mar 2012 | Jun 2012 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹20 Cr | ₹20 Cr | ₹16 Cr | ₹4,53,000 Cr | ₹3,98,000 Cr | ₹1,40,000 Cr | ₹1,23,000 Cr | ₹3,44,000 Cr |
| EBITDA | ₹2 Cr | ₹-1 Cr | ₹2 Cr | ₹-16,10,000 Cr | ₹-16,25,000 Cr | ₹-50,15,000 Cr | ₹-4,95,000 Cr | ₹-77,000 Cr |
| Net Profit | ₹1 Cr | ₹-2 Cr | ₹0 Cr | ₹-16,41,000 Cr | ₹-17,54,000 Cr | ₹-50,25,000 Cr | ₹-5,32,000 Cr | ₹-93,000 Cr |
| EPS | — | — | — | -0.2 | -0.22 | -0.62 | -0.07 | -0.01 |
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹80 Cr | ₹168 Cr | ₹198 Cr | ₹8 Cr | ₹8 Cr | ₹6 Cr | ₹2 Cr | ₹0 Cr |
| EBITDA | ₹4 Cr | ₹5 Cr | ₹4 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹-7 Cr | ₹-1 Cr |
| Net Profit | ₹1 Cr | ₹1 Cr | ₹-1 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹-8 Cr | ₹-1 Cr |
| EPS | 0.4 | 0.76 | -0.33 | 1.16 | -0.49 | -0.12 | -9.89 | -1.04 |
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹105 Cr | ₹117 Cr | ₹21 Cr | ₹21 Cr | ₹21 Cr | ₹7 Cr | ₹4 Cr | ₹5 Cr |
| Total Liabilities | ₹80 Cr | ₹93 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹4 Cr | ₹2 Cr | ₹3 Cr |
| Equity | ₹25 Cr | ₹24 Cr | ₹11 Cr | ₹11 Cr | ₹11 Cr | ₹3 Cr | ₹2 Cr | ₹1 Cr |
| Total Debt | — | — | — | — | — | — | — | ₹1 Cr |
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | ₹18 Cr | ₹2 Cr | ₹0 Cr | ₹-3 Cr | ₹0 Cr | ₹-55,96,000 Cr |
| Investing | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹12 Cr | ₹0 Cr | ₹3,90,000 Cr |
| Financing | ₹-10 Cr | ₹0 Cr | ₹1 Cr | ₹-3 Cr | ₹0 Cr | ₹75,28,000 Cr |
| Free Cash Flow | ₹18 Cr | ₹2 Cr | ₹0 Cr | ₹-3 Cr | ₹0 Cr | ₹-55,96,000 Cr |
Healthcare · Drug Manufacturers - Specialty & Generic
Ortin Global Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders; formulations, such as anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helmenthetics, analgesics and antipyretics, anti-biotics-quinolones, anti-biotic-pencillins, antifungal, cephalosporins, and macrolides. Its formulations also include chemo therapeutics, antacids and anti-ulcerants, anti-spasmodics, calcium and iron preparations, anti-arthritic drugs, protein supplements, enzymes, and vitamins, as well as psychiatry, appetizer, gynaec, and anti-retroviral products. In addition, the company offers active pharmaceutical ingredient (API) intermediates, including anti-retroviral, anti-diabetics, analgesics and antipyretics, anti-biotics, antifungal, antacids and anti-ulcerants, and anti-malarials; and manufactures fine chemicals, and grignard and alkali metal products. Further, the company provides services in the areas of process development, process and product characterization, analytical research and development, and assay development; research and development services for new formulation brands; and diagnostic services comprising development of rapid flow kits, assays, and reagents. Additionally, it undertakes long-term contracts for manufacturing intermediates and developing new APIs; operates as a merchant exporter of pharmaceutical finished formulations; and engages in real estate. The company was formerly known as Ortin Laboratories Limited and changed its name to Ortin Global Limited in June 2024. Ortin Global Limited was incorporated in 1986 and is headquartered in Hyderabad, India.
www.ortinlabsindia.com ↗As of 2026-03-31
Quarterly — figures in %. Latest 12 quarters.
| Period | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 7.4% | 7.4% | 7.4% | 1.2% | 1.2% | 1.2% | 1.2% | 1.2% | 1.2% | 1.2% | 1.2% | 1.2% |
| FIIs | 0% | 0% | 0% | 0% | 6.2% | 6.2% | 6.2% | 6.5% | 6.5% | 1.7% | 1.7% | 1.7% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 92.6% | 92.6% | 92.6% | 98.8% | 92.5% | 92.5% | 92.5% | 92.2% | 92.2% | 97.1% | 97.1% | 97.1% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 12,181 | 11,836 | 12,314 | 12,192 | 11,952 | 12,165 | 12,094 | 12,144 | 12,034 | 12,060 | 11,834 | 11,452 |
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
| Name | Category | Stake | Shares |
|---|---|---|---|
| Suresh Gadalay | Public Shareholding | 6.1% | 4,96,406 |
| Rajesh Poddar | Public Shareholding | 4.7% | 3,81,467 |
| Mir Ata Ali Khan | Public Shareholding | 2.6% | 2,07,231 |
| Wave Capital Limited | Public Shareholding | 1.7% | 1,36,676 |
| Prabha Rameshkumar Gupta | Public Shareholding | 1.4% | 1,16,420 |
| Subhash Lalitprasad Yadav | Public Shareholding | 1.4% | 1,13,000 |
| Nallavolu Jayamma | Public Shareholding | 1.2% | 1,00,227 |
| Saadvik Raghuram Yellareddygari | Public Shareholding | 1.1% | 85,000 |
| Sanka Tandav Krishna | Shareholding of Promoter and Promoter Group | 0.5% | 40,512 |
| Venkata Sujatha Sanka | Shareholding of Promoter and Promoter Group | 0.3% | 21,944 |
| Lakshmi Sravani Dasari | Shareholding of Promoter and Promoter Group | 0.3% | 20,000 |
| Murali Krishna Murthy Sanka | Shareholding of Promoter and Promoter Group | 0.2% | 17,844 |
| Balaji Venkateswarlu Sanka | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Sanka Sharath Kumar | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Venkata Ratnamma Sanka | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Srinivasa Kumar Sanka | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Sanka Hema Kumari | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Venkata Subbamma Sanka | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Sanka Ravi Sankar | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Sanka Satya Praveen Kumar | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Sanka Naga Jyothi | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Krishna Karthik Sanka | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Murali Krishna Murthy Sanka | 0 | 0% | 2026-03-31 |
| Balaji Venkateswarlu Sanka | 0 | 0% | 2026-03-31 |
| Sanka Sharath Kumar | 0 | 0% | 2026-03-31 |
| Venkata Ratnamma Sanka | 0 | 0% | 2026-03-31 |
| Venkata Sujatha Sanka | 0 | 0% | 2026-03-31 |
| Venkata Subbamma Sanka | 0 | 0% | 2026-03-31 |
| Lakshmi Sravani Dasari | 0 | 0% | 2026-03-31 |
| Srinivasa Kumar Sanka | 0 | 0% | 2026-03-31 |
| Sanka Hema Kumari | 0 | 0% | 2026-03-31 |
| Sanka Tandav Krishna | 0 | 0% | 2026-03-31 |
| Sanka Ravi Sankar | 0 | 0% | 2026-03-31 |
| Sanka Satya Praveen Kumar | 0 | 0% | 2026-03-31 |
| Name | Designation | Year |
|---|---|---|
| S Murali Krishna Murthy | Managing Director | 2025 |
| Pramod Dnyandeo Wag He | Non Executive Director | 2025 |
| Mounika Pammi | Independent Director | 2025 |
| Prashant Prakash Sawant | Whole-time Director | 2025 |
| Prakruti Prakash Sawant | Whole-time Director | 2025 |
| Sarang Balbhimrao Patodekar | Chairman & Independent Directo | 2025 |
| Ajay Vishwakarma | Independent Director | 2025 |
| Madhu Solanki | Company Sec. & Compli. Officer | 2025 |
| Segment | Revenue | Share |
|---|---|---|
| Manufacture of Pharmaceutical Produ | ₹0 Cr | — |
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹10 | 10 | 8 | 8 |
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 0 | 0 | 0 | 1 | 0 | 2 |
| 2025 | 0 | 0 | 0 | 1 | 0 | 2 |
| 2025 | 0 | 0 | 0 | 0 | 0 | 0 |
28 recent disclosure(s)
2 disclosure(s)
📍 D No 1-8-B4 Ground Floor F3, HIG Block-4 Street No 3, Hyderabad, Telangana, 500044
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search